Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23861627 | 0.83 | PTPN22 (0.50) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL5596136 | 0.80 | PTPN22 (0.47) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL23861443 | 0.80 | ESR1 (0.47) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL23499948 | 0.77 | PTPN22 (0.52) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL20398800 | 0.75 | PTPN22 (0.54) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL2221239 | 0.75 | PTPN22 (0.54) | HSD17B10CYP1A2CYP2C19CYP2C9PTPN22 | |
| SCHEMBL31356444 | 0.75 | PTPN22 (0.54) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL7296516 | 0.75 | PTPN22 (0.54) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL1603439 | 0.75 | PTPN22 (0.54) | HSD17B10CYP1A2CYP2C19CYP2C9HPGD | |
| SCHEMBL23861563 | 0.74 | PTPN22 (0.48) | HSD17B10CYP1A2CYP2C19CYP2C9PTPN22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144916-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | The Trustees of the University of Pennsylvania (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2008124812-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-0918514-B9 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-0918514-B1 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2004-07-01 | — | — | US | disclosed |
| US-20030119784-A1 | Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| US-6495567-B1 | REDUCING CHLORIDE SECRETION; PREVENTING DEHYDRATION, ACIDOSIS, DEATH AND IMPAIRED GROWTH | BETH ISRAEL DEACONESS MEDICAL CENTER | 2002-12-17 | — | — | US | disclosed |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2002-08-29 | — | — | US | disclosed |
| US-6331564-B1 | TREATING DIARRHEA CAUSED BY INFLAMMATORY BOWEL DISEASE, AUTOIMMUNE DISEASES SUCH AS LUPUS, GLOMERULONEPHRITIS | ION PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0918514-A4 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | HARVARD COLLEGE (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119784-A1 | Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds | SLC10A2, VIP, CLCN2 | HSD17B10 980/4885CYP1A2 950/4885CYP2C19 976/4885 |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | HSD17B10 1995/4885CYP1A2 3595/4885CYP2C19 2564/4885 |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | HSD17B10 1995/4885CYP1A2 3595/4885CYP2C19 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.